No connection

Search Results

ACIU vs PRE

ACIU
AC Immune SA
BEARISH
Price
$3.02
Market Cap
$303.3M
Sector
Healthcare
AI Confidence
85%
PRE
Prenetics Global Limited
NEUTRAL
Price
$17.83
Market Cap
$300.9M
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
ACIU
--
PRE
--
Forward P/E
ACIU
4.88
PRE
-26.22
P/B Ratio
ACIU
3.83
PRE
1.64
P/S Ratio
ACIU
69.38
PRE
3.26
EV/EBITDA
ACIU
-2.8
PRE
-6.5

Profitability

Gross Margin
ACIU
0.0%
PRE
52.98%
Operating Margin
ACIU
-1671.88%
PRE
-33.27%
Profit Margin
ACIU
0.0%
PRE
-63.13%
ROE
ACIU
-74.63%
PRE
-31.79%
ROA
ACIU
-21.96%
PRE
-11.02%

Growth

Revenue Growth
ACIU
-96.3%
PRE
248.6%
Earnings Growth
ACIU
--
PRE
--

Financial Health

Debt/Equity
ACIU
0.07
PRE
0.01
Current Ratio
ACIU
1.16
PRE
3.01
Quick Ratio
ACIU
1.12
PRE
2.76

Dividends

Dividend Yield
ACIU
--
PRE
--
Payout Ratio
ACIU
0.0%
PRE
0.0%

AI Verdict

ACIU BEARISH

ACIU's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a target price of $8.98, the company exhibits catastrophic profitability metrics—negative ROE (-74.63%), gross and net margins at 0%, and a staggering -1671.88% operating margin. Revenue has collapsed by 96.3% YoY, and the stock trades at an absurd Price/Sales of 69.38, far exceeding peer benchmarks. The 52-week range ($1.43–$4.00) and 5-year decline of 62.7% underscore long-term underperformance, despite recent short-term price gains.

Strengths
Recent quarterly earnings have consistently beaten estimates (3/4 in last 4 quarters)
Positive earnings surprise in the most recent quarter (+17.1%) and improving Q/Q EPS growth (+12.5%)
Low debt/equity ratio (0.07) suggests conservative capital structure
Risks
Piotroski F-Score of 1/9 signals severe financial deterioration and operational failure
Negative operating margin (-1671.88%) and zero profit margin indicate fundamental unprofitability
96.3% YoY revenue collapse suggests business model or pipeline failure
PRE NEUTRAL

Prenetics Global Limited presents a high-risk, high-reward profile characterized by explosive revenue growth (248.6% YoY) contrasted with deep operational losses. The Piotroski F-Score of 4/9 indicates a stable but not strong financial position, while the absence of an Altman Z-Score is mitigated by an exceptionally low Debt/Equity ratio (0.01) and strong liquidity (Current Ratio 3.01). While analysts maintain a 'strong_buy' rating with a target of $31.25, the 0/100 technical trend and low insider sentiment (40/100) suggest significant near-term headwinds despite the long-term growth trajectory.

Strengths
Hyper-growth revenue trajectory (248.6% YoY, 567.66% Q/Q)
Pristine balance sheet with negligible debt (Debt/Equity 0.01)
Strong liquidity position with a Current Ratio of 3.01
Risks
Severe lack of profitability (Profit Margin -63.13%)
Bearish technical trend (0/100) indicating negative price momentum
Low insider sentiment (40/100) suggesting lack of internal confidence

Compare Another Pair

ACIU vs PRE: Head-to-Head Comparison

This page compares AC Immune SA (ACIU) and Prenetics Global Limited (PRE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile